Showing posts with label PhD. Show all posts
Showing posts with label PhD. Show all posts

Wednesday, February 26, 2014

Secondhand Smoke Exposure Linked to Adverse Pregnancy Outcomes

Roswell Park/University at Buffalo study finds significant risk for women who never smoked

BUFFALO, N.Y. — Secondhand smoking is linked with pregnancy loss, including miscarriage, stillbirth and tubal ectopic pregnancy, according to new research from scientists at Roswell Park Cancer Institute (RPCI) and the University at Buffalo (UB). The study findings, published online by the journal Tobacco Control, mark a significant step toward clarifying the risks of secondhand smoke exposure.

“This study demonstrated that pregnancy outcomes can be correlated with secondhand smoking. Significantly, women who have never smoked but were exposed to secondhand smoke were at greater risk for fetal loss,” says the study’s lead investigator, Andrew Hyland, PhD, Chair of RPCI’s Department of Health Behavior.

While there was previously some evidence that smoking during pregnancy was associated with the three outcomes of fetal loss studied here — spontaneous abortion or miscarriage (loss of a fetus before 20 weeks of gestation), stillbirth (loss of a fetus after 20 or more weeks of gestation) and tubal ectopic pregnancy — such evidence for secondhand smoke (SHS) exposure had been limited. This study is significant in two ways: One, it considered lifetime SHS exposure rather than only during pregnancy or reproductive years, taking into consideration smoke exposure in participants’ childhood and adult years. Two, the comparison group of never-smokers was limited to women without any SHS exposure, producing a truer control group compared to previous studies.

The large sample size and comprehensive assessment of SHS exposure added strength to the findings. Historical reproductive data, current and former smoking status, and details about SHS exposure over lifetime were collected from the Women’s Health Initiative Observational Study. This allowed for a study group of 80,762 women.

“The statistical power gained from the large cohort of women that was available is noteworthy,” added co-author Jean Wactawski-Wende, PhD, Professor in the Departments of Social and Preventive Medicine and Obstetrics and Gynecology, and Vice Provost for Research Advancement and Strategic Initiatives at UB. “As a result of the Women’s Health Initiative Observational Study, participants came from a broad range of geographic areas and had multiple ethnic, educational and socio-economic backgrounds. This allowed for a comprehensive assessment of detailed information on exposures, outcomes and potential confounders.”

Women with the highest levels of SHS exposure — despite never having smoked themselves — had significantly greater estimates of risk for all three adverse pregnancy outcomes, and these risks approached the risk seen among women who smoke (those who smoked more than 100 cigarettes in their lifetime). The highest levels of lifetime SHS exposure were defined by childhood exposure for longer than 10 years, adult home exposure for more than 20 years and adult work exposure for more than 10 years.

“This study offers new information for women regarding the lifetime impact secondhand smoke can have on reproductive outcomes and their ability to successfully bring a pregnancy to full term,” says Dr. Hyland. “The strength of the study also provides public-health professionals and others with information upon which to base health guidelines about the significant consequences of secondhand smoke.”


Saturday, December 10, 2011

ROSWELL PARK WILL LEAD $5.1M GENE-SEQUENCING EFFORT FUNDED BY NYS INITIATIVE


Effort will examine genetic factors in common diseases and advance field of personalized medicine

BUFFALO, NY — The Roswell Park Cancer Institute Genome Project was approved December 8, 2011 as part of Gov. Andrew Cuomo’s Regional Economic Development Council initiative. RPCI will lead this project, which will compile and analyze the detailed genetic data (the “genomes”) of Western New York citizens. This will significantly enhance our ability to develop personalized, more effective medical care plans and treatments for citizens of Western New York (WNY) — and beyond.
The $5.1 million award for the RPCI Genome Project covers the two-year pilot phase of the project. During this phase of the project, 1,000 area residents will be asked to donate a blood sample and provide detailed medical information; all these data will be collected in a fully protected way to ensure the privacy of all participants. The Genome Project will examine genetic factors that play a role in cancer as well as common diseases such as diabetes, heart disease and hypertension.
RPCI President and CEO Donald L. Trump, MD, FACP, and Deputy Director Candace Johnson, PhD, will lead the RPCI Genome Project as Co-Principal Investigators. Partners include the University at Buffalo, Kaleida Health, the Catholic Health System and Erie County Medical Center as well as the three major health insurers in WNY (HealthNow/BlueCross BlueShield, Independent Health and Univera Healthcare), The P2 Collaborative and HEALTHeLINK.
The Roswell Park Cancer Institute Genome Project was championed by WNY Regional Economic Development Council (WNYREDC) Co-Chairs Satish K. Tripathi, University at Buffalo President, and Howard A. Zemsky, Managing Partner of Larkin Development Group, along with Andrew Rudnick, President of the Buffalo Niagara Partnership and Health & Life Sciences Co-Chair for the WNYREDC.
“Together, they ably and energetically oversaw the maturation and development of this proposal, working closely with RPCI at every stage,” said Dr. Trump. “We are grateful for the leadership they, Governor Cuomo and all the members of the Western New York Regional Council have provided through this ambitious development program, and eagerly look forward to implementing this effort.”
For more information, visit RPCI’s website athttp://www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci@roswellpark.org.